BBH - ETF AI Analysis
Top Page
VanEck Biotech ETF (BBH)
Rating:72Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered solid gains so far this year and over the past few months, showing positive momentum in the biotech space.
Leading Biotech Holdings
Several of the largest positions, including major biotech companies, have shown strong or steady performance, helping support the fund’s returns.
Moderate Expense Ratio
The fund’s expense ratio is reasonable for a specialized biotech ETF, allowing investors to access the sector without excessively high ongoing costs.
Negative Factors
High Sector Concentration
Almost all of the ETF’s assets are in the health care/biotech sector, which means performance is heavily tied to the fortunes of this single industry.
Limited Geographic Diversification
The portfolio is almost entirely invested in U.S. companies, offering little protection if the U.S. market or regulatory environment for biotech weakens.
Mixed Performance Among Top Holdings
Some of the largest positions have recently shown weak or negative performance, which can offset gains from stronger holdings and add volatility.
BBH vs. SPDR S&P 500 ETF (SPY)
AUM489.51M
RegionGlobal
Expense Ratio0.35%
Beta0.59
IssuerVanEck
Inception DateDec 20, 2011
Dividend Yield0.39%
Asset ClassEquity
Index TrackedMVIS US Listed Biotech 25
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume15,525
30 Day Avg. Volume7,337
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
256.44Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering24
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BBH Summary
The VanEck Biotech ETF (BBH) is a fund that follows the MVIS US Listed Biotech 25 Index and focuses on U.S. biotechnology companies. It holds firms that develop new medicines, genetic treatments, and medical tests, including well-known names like Amgen and Gilead Sciences. Someone might invest in BBH if they want growth potential from medical breakthroughs and a simple way to spread their money across many biotech stocks instead of picking just one. However, this ETF is heavily concentrated in biotech, so its price can swing a lot and may fall sharply if drug trials fail or health care stocks drop.
How much will it cost me?The VanEck Biotech ETF (BBH) has an expense ratio of 0.35%, meaning you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused ETF that targets biotechnology companies, which often require more active management to track this specialized market. It’s important to consider whether the potential growth in this niche sector aligns with your investment goals.
What would affect this ETF?The VanEck Biotech ETF (BBH) could benefit from advancements in biotechnology, such as breakthroughs in drug development and genetic research, as well as increased global demand for innovative health solutions. However, it may face challenges from regulatory hurdles, high research costs, and potential economic downturns that could impact funding for biotech companies. Additionally, changes in interest rates could affect the financial performance of its top holdings like Gilead Sciences and Amgen.
BBH Top 10 Holdings
BBH is a pure biotech play, with performance largely steered by a handful of heavyweight drug makers. Amgen and Gilead are both rising steadily, giving the fund a solid, blue-chip backbone, while Vertex and Regeneron add more growth-oriented momentum as their pipelines advance. Moderna has been a wild card, with strong recent price action despite underlying business challenges, injecting extra volatility into returns. Natera and Illumina round out the story with upbeat, innovation-driven moves. Overall, this is a globally focused, lab-coat-heavy portfolio concentrated in biotech leaders.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Amgen | 15.46% | $74.29M | $233.78B | 50.30% | 77 Outperform | |
| Gilead Sciences | 12.66% | $60.82M | $180.64B | 28.95% | 78 Outperform | |
| Vertex Pharmaceuticals | 8.43% | $40.50M | $137.30B | 38.53% | 78 Outperform | |
| Regeneron | 6.76% | $32.47M | $81.77B | 36.76% | 78 Outperform | |
| Moderna | 5.76% | $27.68M | $55.09B | 472.81% | 59 Neutral | |
| Revolution Medicines | 5.23% | $25.14M | $44.56B | 447.48% | 52 Neutral | |
| Natera | 5.16% | $24.78M | $47.03B | 93.91% | 73 Outperform | |
| IQVIA Holdings | 4.91% | $23.61M | $43.08B | 37.18% | 73 Outperform | |
| Argenx Se | 4.77% | $22.91M | $64.89B | 43.67% | 79 Outperform | |
| Illumina | 3.45% | $16.58M | $32.55B | 115.68% | 71 Outperform |
BBH Technical Analysis
Positive
―
Price Trends
216.51
Positive
201.74
Positive
196.83
Positive
Market Momentum
8.39
Positive
69.76
Neutral
74.54
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 232.54, equal to the 50-day MA of 216.51, and equal to the 200-day MA of 196.83, indicating a bullish trend. The MACD of 8.39 indicates Positive momentum. The RSI at 69.76 is Neutral, neither overbought nor oversold. The STOCH value of 74.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBH.
BBH Peer Comparison
Comparison Results
Performance Comparison
BBH
VanEck Biotech ETF
241.12
73.59
43.93%
GII
SPDR S&P Global Infrastructure ETF
―
―
―
AVRE
Avantis Real Estate ETF
―
―
―
ROBT
First Trust Nasdaq Artificial Intelligence & Robotics ETF
―
―
―
JETS
U.S. Global Jets ETF
―
―
―
CANC
Tema Oncology ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents